Anticoagulation in patients with impaired renal function and with haemodialysis: Anticoagulant effects, efficacy, safety, therapeutic options

Hamostaseologie

Volumn 35, Issue 1, 2015, Pages 77-83

  Harenberg, Job ^a   Hentschel, V A T ^a   Du, S ^a   Zolfaghari, S ^a   Kramer R ^a   Weiss, C ^a   Kramer B K ^a   Wehling, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Direct thrombin inhibitors; Heparin; Low molecular weight heparin; Oral direct factor xa inhibitors; Renal impairment; Vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; DABIGATRAN; DALTEPARIN; DANAPAROID; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; NADROPARIN; RIVAROXABAN; TINZAPARIN; FIBRINOLYTIC AGENT;

ANTICOAGULATION; AREA UNDER THE CURVE; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELIMINATION HALF-LIFE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; METABOLITE; PLASMA PROTEIN BINDING; REVIEW; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; HEMORRHAGE; HEMOSTASIS; KIDNEY FUNCTION TEST; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; KIDNEY FUNCTION TESTS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

EID: 84939559214     PISSN: 07209355     EISSN: 25675761     Source Type: Journal    
DOI: 10.5482/hamo-14-08-0036     Document Type: Review

References (48)

1. Holbrook A, Schulman S, Witt DM et al. Evidencebased management of anticoagulant therapy. Chest 2012; 141 (2 Suppl): e152S-e184S.
2. Bauer KA. Pros and cons of new oral anticoagulants. American Society of Hematology Education Program. 2013; 2013: 464-470.
3. Ageno W, Gallus AS, Wittkowsky A et al. Oral anticoagulant therapy. Chest 2012; 141 (2 Suppl):e44S-e88S.
4. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy. Semin Throm Hemost 2008; 34: 39-57.
5. Guyatt GH, Eikelboom JW, Gould MK et al. Approach to Outcome Measurement in the Prevention of Thrombosis in Surgical and Medical Patients. Chest 2012; 141 (2 Suppl): e185S-e194S.
6. Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia. Chest 2012; 141 (2 Suppl): e495S-e530S.
7. Van De Car DA, Rao SV, Ohman EM. Bivalirudin. Expert Rev Cardiovasc Ther 2010; 8: 1673-1681.
8. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 2002; 28: 467-482.
9. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012; 129: 407-417.
10. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005; 5: 291-305.
11. Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C. The aging kidney revisited. Ageing Res Rev 2014; 14: 65-80.
12. Group KDIGOKCW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
13. Bauersachs RM. Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Intern Med 2014; 25: 600-606.
14. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage. J Am Coll Cardiol 2011; 58: 395-401.
15. Harenberg J, Bauersachs R, Diehm C et al. Anticoagulation in the elderly. Internist 2010; 51: 1446-1455.
16. Caranobe C, Barret A, Gabaig AM et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res 1985; 40:129-133.
17. Sanderink GJ, Guimart CG, Ozoux ML et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231.
18. Hoffmann U, Harenberg J, Bauer K et al. Bioequivalence of subcutaneous and intravenous bodyweight- independent high-dose low-molecularweight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagul Fibrinolysis 2002; 13: 289-296.
19. Dorsch O, Krieter DH, Lemke HD et al. A multicenter, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis. BMC Nephrol 2012; 13: 50.
20. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Ther Drug Monit 2010; 32: 482-488.
21. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684.
22. Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin. Eur J Clin Pharmacol 2012; 68: 757-765.
23. Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate- to-severe renal impairment. J Thromb Haemost 2011; 9: 1966-1972.
24. Leizorovicz A, Siguret V, Mottier D et al. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis. Thromb Res 2011; 128: 27-34.
25. Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008;123 Suppl 1:S58-61.
26. DeCarolis DD, Thorson JG, Clairmont MA et al. Enoxaparin outcomes in patients with moderate renal impairment. Arch Intern Med 2012; 172: 1713-1718.
27. Harenberg J, Haaf B, Dempfle CE et al. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant 1995; 10: 217-222.
28. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure. J Am Soc Nephrol 2004; 15: 3192-3206.
29. Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int 2011; 15 (Suppl 1): S43-S48.
30. Nowak G. New anticoagulants for secondary haemostasis--anti IIa inhibitors. Hämostaseologie 2009; 29: 256-259.
31. Wang LC, Huhle G, Malsch R et al. Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II. Eur J Clin Invest 1999; 29: 232-237.
32. Harenberg J, Jorg I, Fenyvesi T, Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 2005; 19: 65-69.
33. Harenberg J, Wehling M. Future of anticoagulant therapy. Cardiovasc Ther 2011; 29: 291-300.
34. Agewall S, Cattaneo M, Collet JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34: 1708-1713.
35. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
36. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants:a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72: 1739-1753.
37. Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
38. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
39. Hori M, Matsumoto M, Tanahashi N et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2013; 77: 632-638.
40. Harenberg J, Kramer S, Du S et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014; 44: 743-752.
41. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37:74-81.
42. Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation. Eur Heart J 2012; 33: 2821-2830.
43. Samama MM, Mendell J, Guinet C et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012; 129: e77-e82.
44. Zahir H, Matsushima N, Halim AB et al. Edoxaban administration following enoxaparin. Thromb Haemost 2012; 108: 166-175.
45. Mendell J, Zahir H, Matsushima N et al. Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor. Am J Cardiovasc Drugs 2013; 13: 331-342.
46. Hokusai VTEI, Buller HR, Decousus H et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
47. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010; 49: 259-268.
48. Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Eur Heart J 2013; 34: 2094-2106.